Mucormycosis

Antachopoulos C, Gea-Banacloche JC, Walsh TJ. Zygomycosis (mucormycosis). In: Hospenthal DR, Rinaldi MG, eds. Diagnosis and treatment of human mycoses. New York, NY: Springer; 2008:227-243.

Antachopoulos C, Gea-Banacloche JC, Walsh TJ. Zygomycosis (mucormycosis). In: Hospenthal DR, Rinaldi MG, eds. Diagnosis and treatment of human mycoses. New York, NY: Springer; 2008:227-43.

Gonzalez CE, Rinaldi MG, Sugar AM. Zygomycosis. Infect Dis Clin North Am. 2002 Dec;16(4):895-914. Abstract

Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005 Jul;18(3):556-69.Full text  Abstract

1. Antachopoulos C, Gea-Banacloche JC, Walsh TJ. Zygomycosis (mucormycosis). In: Hospenthal DR, Rinaldi MG, eds. Diagnosis and treatment of human mycoses. New York, NY: Springer; 2008:227-243.

2. Antachopoulos C, Gea-Banacloche JC, Walsh TJ. Zygomycosis (mucormycosis). In: Hospenthal DR, Rinaldi MG, eds. Diagnosis and treatment of human mycoses. New York, NY: Springer; 2008:227-43.

3. Vilela R, Mendoza L. Human Pathogenic Entomophthorales. Clin Microbiol Rev. 2018 Aug 29;31(4):e00014-18.Full text  Abstract

4. Alastruey-Izquierdo A, Hoffmann K, de Hoog GS, et al. Species recognition and clinical relevance of the zygomycetous genus Lichtheimia (syn. Absidia pro parte, Mycocladus). J Clin Microbiol. 2010 Jun;48(6):2154-70.Full text  Abstract

5. Gonzalez CE, Rinaldi MG, Sugar AM. Zygomycosis. Infect Dis Clin North Am. 2002 Dec;16(4):895-914. Abstract

6. Almyroudis NG, Sutton DA, Linden P, et al. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant. 2006 Oct;6(10):2365-74.Full text  Abstract

7. Roilides E, Zaoutis TE, Walsh TJ. Invasive zygomycosis in neonates and children. Clin Microbiol Infect. 2009 Oct;15(suppl 5):50-4. Abstract

8. Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect. 2004 Mar;10(suppl 1):31-47.Full text  Abstract

9. Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005 Jul;18(3):556-69.Full text  Abstract

10. Neblett Fanfair R, Benedict K, Bos J, et al. Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011. N Engl J Med. 2012 Dec 6;367(23):2214-25.Full text  Abstract

11. Moorthy A, Gaikwad R, Krishna S, et al. SARS-CoV-2, uncontrolled diabetes and corticosteroids-an unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis. J Maxillofac Oral Surg. 2021 Mar 6;1-8.Full text  Abstract

12. John TM, Jacob CN, Kontoyiannis DP. When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis. J Fungi (Basel). 2021 Apr 15;7(4):2021 Apr 15;7(4):298.Full text  Abstract

13. Reyes HM, Tingle EJ, Fenves AZ, et al. Pulmonary invasive mucormycosis in a patient with secondary iron overload following deferoxamine therapy. Proc (Bayl Univ Med Cent). 2008 Oct;21(4):378-81.Full text  Abstract

14. Sahin B, Paydas S, Cosar E, et al. Role of granulocyte colony-stimulating factor in the treatment of mucormycosis. Eur J Clin Microbiol Infect Dis. 1996 Nov;15(11):866-9. Abstract

15. Sugar AM. Agents of mucormycosis and related species. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 6th ed. Philadelphia, PA: Churchill Livingstone; 2005:2973-81.

16. El Deeb Y, Al Soub H, Almaslamani M, et al. Post-traumatic cutaneous mucormycosis in an immunocompetent patient. Ann Saudi Med. 2005 Jul-Aug;25(4):343-5. Abstract

17. Elsiesy H, Saad M, Shorman M, et al. Invasive mucormycosis in a patient with liver cirrhosis: case report and review of the literature. Hepat Mon. 2013 Aug 11;13(8):e10858.Full text  Abstract

18. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005 Apr 15;191(8):1350-60.Full text  Abstract

19. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005 Sep 1;41(5):634-53.Full text  Abstract

20. Ledgard JP, van Hal S, Greenwood JE. Primary cutaneous zygomycosis in a burns patient: a review. J Burn Care Res. 2008 Mar-Apr;29(2):286-90. Abstract

21. McAdams HP, Rosado de Christenson M, Strollo DC, et al. Pulmonary mucormycosis: radiologic findings in 32 cases. AJR Am J Roentgenol. 1997 Jun;168(6):1541-8. Abstract

22. Kobayashi M, Togitani K, Machida H, et al. Molecular polymerase chain reaction diagnosis of pulmonary mucormycosis caused by Cunninghamella bertholletiae. Respirology. 2004 Aug;9(3):397-401. Abstract

23. Rickerts V, Loeffler J, Bohme A, et al. Diagnosis of disseminated zygomycosis using a polymerase chain reaction assay. Eur J Clin Microbiol Infect Dis. 2001 Oct;20(10):744-5. Abstract

24. Hammond SP, Bialek R, Milner DA, et al. Molecular methods to improve diagnosis and identification of mucormycosis. J Clin Microbiol. 2011 Jun;49(6):2151-3.Full text  Abstract

25. Bernal-Martínez L, Buitrago MJ, Castelli MV, et al. Development of a single tube multiplex real-time PCR to detect the most clinically relevant Mucormycetes species. Clin Microbiol Infect. 2013 Jan;19(1):E1-7.Full text  Abstract

26. Kolekar JS. Rhinocerebral mucormycosis: a retrospective study. Indian J Otolaryngol Head Neck Surg. 2015 Mar;67(1):93-6.Full text  Abstract

27. Kontoyiannis DP, Lewis RE. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am. 2006 Sep;20(3):581-607. Abstract

28. Turunc T, Demiroglu YZ, Aliskan H, et al. Eleven cases of mucormycosis with atypical clinical manifestations in diabetic patients. Diabetes Res Clin Pract. 2008 Nov;82(2):203-8. Abstract

29. Gamba JL, Woodruff WW, Djang WT, et al. Craniofacial mucormycosis: assessment with CT. Radiology. 1986 Jul;160(1):207-12. Abstract

30. Glazier M, Nusair S, Breuer R, et al. The role of BAL in the diagnosis of pulmonary mucormycosis. Chest. 2000 Jan;117(1):279-82. Abstract

31. Lass-Florl C, Resch G, Nachbaur D, et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis. 2007 Oct 1;45(7):e101-4.Full text  Abstract

32. Shahapure AG, Patankar RV, Bhatkhande R. Gastric mucormycosis. Indian J Gastroenterol. 2002 Nov-Dec;21(6):231-2. Abstract

33. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood. 1997 Aug 1;90(3):999-1008.Full text  Abstract

34. Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019 Dec;19(12):e405-e421.Full text  Abstract

35. Spellberg B, Ibrahim AS. Recent advances in the treatment of mucormycosis. Curr Infect Dis Rep. 2010 Nov;12(6):423-9.Full text  Abstract

36. Arndt S, Aschendorff A, Echternach M, et al. Rhino-orbital-cerebral mucormycosis and aspergillosis: differential diagnosis and treatment. Eur Arch Otorhinolaryngol. 2009 Jan;266(1):71-6. Abstract

37. Dan M. Mucormycosis of the head and neck. Curr Infect Dis Rep. 2011 Apr;13(2):123-31. Abstract

38. Falci DR, Pasqualotto AC. Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infect Drug Resist. 2013 Oct 22;6:163-74.Full text  Abstract

39. Enoch DA, Aliyu SH, Sule O, et al. Posaconazole for the treatment of mucormycosis. Int J Antimicrob Agents. 2011 Dec;38(6):465-73. Abstract

40. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009 Jan;53(1):24-34.Full text  Abstract

41. Ibrahim AS, Edwards JE Jr, Fu Y, et al. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother. 2006 Nov;58(5):1070-3.Full text  Abstract

42. Perkhofer S, Locher M, Cuenca-Estrella M, et al. Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. Antimicrob Agents Chemother. 2008 Jul;52(7):2636-8.Full text  Abstract

43. Gebremariam T, Gu Y, Singh S, et al. Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis. J Antimicrob Chemother. 2021 Jul 15;dkab233.Full text  Abstract

44. Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008 Aug 1;47(3):364-71.Full text  Abstract

45. Spellberg B, Walsh TJ, Kontoyiannis DP, et al. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis. 2009 Jun 15;48(12):1743-51.Full text  Abstract

46. Nattusamy L, Kalai U, Hadda V, et al. Bronchoscopic instillation of liposomal amphotericin B in management of nonresponding endobronchial mucormycosis. Lung India. 2017 Mar-Apr;34(2):208-9.Full text  Abstract

47. Alfageme I, Reina A, Gallego J, et al. Endobronchial instillations of amphotericin B: complementary treatment for pulmonary mucormycosis. J Bronchology Interv Pulmonol. 2009 Jul;16(3):214-5. Abstract

48. Anderson A, McManus D, Perreault S, et al. Combination liposomal amphotericin B, posaconazole and oral amphotericin B for treatment of gastrointestinal Mucorales in an immunocompromised patient. Med Mycol Case Rep. 2017 May 24;17:11-3.Full text  Abstract

49. Vashi N, Avedian R, Brown J, et al. Successful surgical and medical treatment of rhizopus osteomyelitis following hematopoietic cell transplantation. Orthopedics. 2012 Oct;35(10):e1556-61. Abstract

50. Gil-Lamaignere C, Simitsopoulou M, Roilides E, et al. Interferon-gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis. 2005 Apr 1;191(7):1180-7.Full text  Abstract

51. John BV, Chamilos G, Kontoyiannis DP. Hyperbaric oxygen as an adjunctive treatment for zygomycosis. Clin Microbiol Infect. 2005 Jul;11(7):515-7.Full text  Abstract

52. Page AV, Evans AJ, Snell L, et al. Primary cutaneous mucormycosis in a lung transplant recipient: case report and concise review of the literature. Transpl Infect Dis. 2008 Dec;10(6):419-25. Abstract

53. Lee FY, Mossad SB, Adal KA. Pulmonary mucormycosis: the last 30 years. Arch Intern Med. 1999 Jun 28;159(12):1301-9.Full text  Abstract

54. Simmons JH, Zeitler PS, Fenton LZ, et al. Rhinocerebral mucormycosis complicated by internal carotid artery thrombosis in a pediatric patient with type 1 diabetes mellitus: a case report and review of the literature. Pediatr Diabetes. 2005 Dec;6(4):234-8. Abstract

55. Koc Z, Koc F, Yerdelen D, et al. Rhino-orbital-cerebral mucormycosis with different cerebral involvements: infarct, hemorrhage, and ophthalmoplegia. Int J Neurosci. 2007 Dec;117(12):1677-90. Abstract